{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:47:23Z","timestamp":1773370043355,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["Extramural Unit Funding"],"award-info":[{"award-number":["Extramural Unit Funding"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"South African National Research Foundation","award":["Unique Grant Numbers 118022 and 120383"],"award-info":[{"award-number":["Unique Grant Numbers 118022 and 120383"]}]},{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","award":["Independent Researcher"],"award-info":[{"award-number":["Independent Researcher"]}],"id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Persistent hepatitis B virus (HBV) infection remains a serious medical problem worldwide, with an estimated global burden of 257 million carriers. Prophylactic and therapeutic interventions, in the form of a vaccine, immunomodulators, and nucleotide and nucleoside analogs, are available. Vaccination, however, offers no therapeutic benefit to chronic sufferers and has had a limited impact on infection rates. Although immunomodulators and nucleotide and nucleoside analogs have been licensed for treatment of chronic HBV, cure rates remain low. Transcription activator-like effector nucleases (TALENs) designed to bind and cleave viral DNA offer a novel therapeutic approach. Importantly, TALENs can target covalently closed circular DNA (cccDNA) directly with the potential of permanently disabling this important viral replicative intermediate. Potential off-target cleavage by engineered nucleases leading to toxicity presents a limitation of this technology. To address this, in the context of HBV gene therapy, existing TALENs targeting the viral core and surface open reading frames were modified with second- and third-generation FokI nuclease domains. As obligate heterodimers these TALENs prevent target cleavage as a result of FokI homodimerization. Second-generation obligate heterodimeric TALENs were as effective at silencing viral gene expression as first-generation counterparts and demonstrated an improved specificity in a mouse model of HBV replication.<\/jats:p>","DOI":"10.3390\/v13071344","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T21:56:52Z","timestamp":1626127012000},"page":"1344","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains"],"prefix":"10.3390","volume":"13","author":[{"given":"Tiffany","family":"Smith","sequence":"first","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Parktown 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashika","family":"Singh","sequence":"additional","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Parktown 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-1894","authenticated-orcid":false,"given":"Kay Ole","family":"Chmielewski","sequence":"additional","affiliation":[{"name":"Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg & Medical Faculty, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristie","family":"Bloom","sequence":"additional","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Parktown 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-4630","authenticated-orcid":false,"given":"Toni","family":"Cathomen","sequence":"additional","affiliation":[{"name":"Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg & Medical Faculty, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-8995","authenticated-orcid":false,"given":"Patrick","family":"Arbuthnot","sequence":"additional","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Parktown 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Ely","sequence":"additional","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Parktown 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/mt.2016.43","article-title":"Progress with Developing Use of Gene Editing To Cure Chronic Infection with Hepatitis B Virus","volume":"24","author":"Ely","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bloom, K., Maepa, M.B., Ely, A., and Arbuthnot, P. (2018). Gene Therapy for Chronic HBV\u2014Can We Eliminate cccDNA?. Genes, 9.","DOI":"10.3390\/genes9040207"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1093\/nar\/gku305","article-title":"TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity","volume":"42","author":"Mussolino","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_7","first-page":"725","article-title":"On target? Tracing zinc-finger-nuclease specificity","volume":"8","author":"Mussolino","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nbt.2808","article-title":"Improving CRISPR-Cas nuclease specificity using truncated guide RNAs","volume":"32","author":"Fu","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1038\/srep13734","article-title":"CRISPR\/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X","volume":"5","author":"Karimova","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/gtc.12437","article-title":"Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus","volume":"21","author":"Sakuma","year":"2016","journal-title":"Genes Cells"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41587-019-0095-1","article-title":"Increasing the specificity of CRISPR sys-tems with engineered RNA secondary structures","volume":"37","author":"Kocak","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41587-019-0186-z","article-title":"Enhancing gene editing specificity by attenuating DNA cleavage kinetics","volume":"37","author":"Miller","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.addr.2020.05.010","article-title":"In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection","volume":"168","author":"Ely","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt1319","article-title":"An improved zinc-finger nuclease architecture for highly specific genome editing","volume":"25","author":"Miller","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nbt1317","article-title":"Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases","volume":"25","author":"Szczepek","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_17","first-page":"74","article-title":"Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures","volume":"8","author":"Doyon","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jmb.2010.04.060","article-title":"Directed Evolution of an Enhanced and Highly Efficient FokI Cleavage Domain for Zinc Finger Nucleases","volume":"400","author":"Guo","year":"2010","journal-title":"J. Mol. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/0092-8674(90)90431-D","article-title":"Translational inactivation of RNA function: Discrimination against a subset of genomic transcripts during HBV nucleocapsid assembly","volume":"63","author":"Nassal","year":"1990","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1006\/bbrc.2000.2209","article-title":"In Situ Demonstration of Inhibitory Effects of Hammerhead Ribozymes That Are Targeted to the Hepatitis Bx Sequence in Cultured Cells","volume":"268","author":"Passman","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","unstructured":"Ely, A., and Arbuthnot, P. (2010). Silencing Hepatitis B Virus Replication with Antiviral Pri-miR Shuttles Generated from Liver-Specific Pol II Promoter, Nova Publishers."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9283","DOI":"10.1093\/nar\/gkr597","article-title":"A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity","volume":"39","author":"Mussolino","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-1-60761-753-2_15","article-title":"A Rapid and General Assay for Monitoring Endogenous Gene Modification","volume":"Volume 649","author":"Guschin","year":"2010","journal-title":"Methods in Molecular Biology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/nar\/gkp446","article-title":"Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles","volume":"37","author":"Ely","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1093\/nar\/gkt1326","article-title":"An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage","volume":"42","author":"Fine","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","article-title":"CRISPResso2 provides accurate and rapid genome editing sequence analysis","volume":"37","author":"Clement","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1242\/bio.20136676","article-title":"Comparison of TALEN scaffolds in Xenopus tropicalis","volume":"2","author":"Nakajima","year":"2013","journal-title":"Biol. Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/zeb.2012.0832","article-title":"Evaluating the Mutagenic Activity of Targeted Endonucleases Containing a Sharkey FokI Cleavage Domain Variant in Zebrafish","volume":"10","author":"Pillay","year":"2013","journal-title":"Zebrafish"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1128\/JVI.00366-08","article-title":"Zinc Finger Proteins Designed to Specifically Target Duck Hepatitis B Virus Covalently Closed Circular DNA Inhibit Viral Transcription in Tissue Culture","volume":"82","author":"Zimmerman","year":"2008","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1093\/nar\/gkw524","article-title":"Probing the impact of chromatin conformation on genome editing tools","volume":"44","author":"Chen","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20672-5","article-title":"TALEN outperforms Cas9 in editing heterochromatin target sites","volume":"12","author":"Jain","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epi-genetic therapy against chronic hepatitis B","volume":"66","author":"Hong","year":"2017","journal-title":"Hepatology"},{"key":"ref_35","unstructured":"WHO (2017). Global Hepatitis Report, World Health Organization."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:29:26Z","timestamp":1760164166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["v13071344"],"URL":"https:\/\/doi.org\/10.3390\/v13071344","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]}}}